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Abstract: We have constructed bispecific immunoglobulin-like immunoadhesins that bind to both
the HIV-envelope glycoproteins: gp120 and gp41. These immunoadhesins have N terminal domains
of human CD4 engrafted onto the N-terminus of the heavy chain of human anti-gp41 mAb 7B2.
Binding of these constructs to recombinant Env and their antiviral activities were compared to that
of the parental mAbs and CD4, as well as to control mAbs. The CD4/7B2 constructs bind to both
gp41 and gp140, as well as to native Env expressed on the surface of infected cells. These constructs
deliver cytotoxic immunoconjugates to HIV-infected cells, but not as well as a mixture of 7B2
and sCD4, and opsonize for antibody-mediated phagocytosis. Most surprisingly, given that 7B2
neutralizes weakly, if at all, is that the chimeric CD4/7B2 immunoadhesins exhibit broad and
potent neutralization of HIV, comparable to that of well-known neutralizing mAbs. These data
add to the growing evidence that enhanced neutralizing activity can be obtained with bifunctional
mAbs/immunoadhesins. The enhanced neutralization activity of the CD4/7B2 chimeras may
result from cross-linking of the two Env subunits with subsequent inhibition of the pre-fusion
conformational events that are necessary for entry.
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1. Introduction
The HIV envelope (Env) glycoproteins, precursor (gp160), surface (gp120), and transmembrane (gp41), are the sole virus-encoded proteins expressed on the surface of virions
and HIV-infected cells. Env is the only viral target of HIV-neutralizing antibodies (Abs).
As such, the anti-Env Ab response is the subject of intense investigation, both for the development of an HIV vaccine [1–6] and for the administration of therapeutic Abs [2,3,7–15].
Well-defined regions of Env have been described as targets of patient-derived neutralizing monoclonal Abs (mAbs), including the gp120 CD4 binding site, variable loops, glycan
shield, interface of gp120/gp41, and the gp41 membrane proximal external region. Preclinical and clinical trials of mAb therapies for HIV have demonstrated that a single mAb
cannot reliably control viremia, whereas combinations of mAbs are more likely to afford
prolonged viral suppression [6,7,9,11,16–20]. To address this, bispecific (or greater) antienvelope Abs/immunoadhesins, consisting of two (or more) domains that bind different
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portions of gp160, have been created, and some demonstrate broad and potent neutralization [8,10,21–32]. Natural mAbs and bispecific constructs that bind to both gp120 and
gp41 have been described [24,25,33–36]. Some of these neutralize quite well [25,34,35],
others only poorly [24,33].
In addition to neutralization of virus infectivity, Abs may mediate anti-HIV effects
through other mechanisms, particularly those that lead to the elimination of HIV-infected
cells. This may be accomplished via Fc-mediated mechanisms, including the induction
of complement and antiviral effects of FcR-expressing cells [16,37–45], or by the delivery
of cytotoxic agents to HIV positive cells. In the course of developing anti-HIV immunoconjugates that use anti-Env mAbs to deliver cytotoxic agents to infected cells (cytotoxic
immunoconjugates), we have noted that mAbs to the gp41 immunodominant loop region
are most effective, particularly when used in association with soluble CD4 [46–49]. In an
effort to design a better Ab for delivering immunoconjugates, we made a series of genetic
constructs in which NH2 -terminal domains of human CD4 were joined to the NH2 -terminus
of the heavy or light chains of the anti-gp41 mAb 7B2. These bispecific immunoadhesins
bind to both gp120 and gp41. Surprisingly the neutralizing abilities of the CD4/7B2 constructs were both broad and potent, far more so than CD4 itself, even though the parental
mAb 7B2 has little if any neutralizing activity. As opposed to neutralization, the ability of
the bispecific immunoadhesin to deliver a cytotoxic immunoconjugate was diminished
when compared to the free components. These constructs may have therapeutic utility for
the prevention of HIV infection, treating active infection by neutralizing virus entry into
uninfected cells, and targeting infected cells for elimination. The data could suggest that
mAbs may neutralize HIV infectivity by limiting the gp120/gp41 structural changes and
dissociation that occur upon receptor binding and are necessary for virus infection.
2. Materials and Methods
2.1. Cells and Reagents
HEK/293T cells were a gift from James Robinson (Tulane University) and were maintained in DMEM, 10% fetal calf serum (GIBCO) in 5% CO2 at 37 ◦ C for transient transfection.
H9/NL4-3 cells were persistently infected with the NL4-3 molecular clone of HIV [50] and
retained a productive infection in virtually 100% of tissue culture cells [46,51]. 293/92UG
cells were the kind gift of Bing Chen and constitutively express the clade C Env 92UG
in its native conformation at the cell surface [52]. THP-1 cells were obtained from ATCC.
Cells were maintained at 37 ◦ C in 5% CO2 as described [24,46].
Soluble, two-domain CD4183 [sCD4, NIH-ARP, [53]] and CD4-IgG2 [PRO542, Progenics Pharmaceuticals, Tarrytown, NY, USA, [54–56]] were used to observe CD4-mediated
effects. CH01-31 is an equal concentration mixture of human anti-gp160 mAbs CH01
and CH31 [57]. 8ANC195 was a gift from P. Bjorkman and binds to determinants at the
gp120/gp41 interface [36]. Chimeric RAC18 (chRAC18, an anti-ricin A chain murine Ab
chimerized to human IgG1/κ) and 23.1D (anti-Lassa) were used as isotype controls [58,59].
Goat anti-human IgG (heavy + light chains) Ab was conjugated to fluorescein isothiocyanate (FITC; Invitrogen) or alkaline phosphatase (AP; Invitrogen). Deglycosylated ricin
A chain (RAC) was conjugated to purified anti-human IgG (Invitrogen) for indirect cytotoxicity assays, as described [24,46].
2.2. Design and Production of Immunoadhesins
Design and production of CD4/7B2 immunoadhesins were as previously described
for double variable domain Abs [24]. Figure 1 and Table 1 summarize the design and
nomenclature of the different immunoadhesins. Parental sequences were derived from
domain 1 and 2 of human CD4 (Genbank accession number BC025782) or from the modified
CD4 designated CD4(D1.22) [60], and from the IgG1/kappa human Ab 7B2 (Genbank
accession numbers JX188438 and JX188439), which binds gp41 immunodominant region at
AA 598-604 (CSGKLIC) [49]. CD4 constructs were joined to 7B2 using linkers described
previously [24]. The first linker is flexible with little structure: (GGGGS)4 , and the second
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(BioTek, Winooski, VT, USA). Data are presented as the mean and SEM of triplicate assays.
2.4. Indirect Immunofluorescence and Flow Cytometry
H9/NL4-3, HEK293T, and 293/92UG cells (1 × 105 ) were stained for flow cytometry
in 200 µL round bottom 96-well plates (Costar, Lowell, MA, USA). Serial dilutions of
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test reagent in PBS, 1% bovine serum albumin, 0.01% Na azide were added to the cells.
Cells were incubated for 2 h at room temperature, washed, stained with FITC-conjugated
goat anti-human IgG (H + L chain specific) secondary Ab for 2 h, and then washed twice
and fixed in 100 µL of 2% paraformaldehyde (PFA). Cells were analyzed on a BectonDickinson LSR II. A total of 10,000 events was collected and the data analyzed using FloJo
software (Treestar, Ashland, OR, USA). Forward scatter (FSC) and side scatter (SSC) gated
data are presented as histograms or graphs of mean fluorescence intensity.
2.5. Cytotoxicity Assay
An indirect cytotoxicity assay was performed to screen unconjugated Abs for their ability to kill infected cells [24,46,63]. Cells (8–12 × 103 per well depending upon cell type) were
plated in triplicate in 96-well flat bottom plates. Controls included: no cells (background)
and cells in the absence of Ab (uninhibited). Abs (200 ng/mL) were incubated with cells for
1 h in RPMI at 37 ◦ C. The cytotoxic immunoconjugate was affinity purified goat anti-human
IgG (Invitrogen) conjugated to deglycosylated ricin A chain using the long chain heterobifunctional cross linking reagent, succinimidyl 6-[3(2-pyridyldithio)proprionamido]hexanoate
(Pierce). The cytotoxic secondary conjugate was added to a final concentration of 300 ng/mL.
The plates were then incubated for 3 days. For the final 6 h of incubation, MTS/PMS substrate (Promega, Madison, WI, USA) was added to each well and plates read at 490 nm.
Results represent the mean and SEM of triplicate samples.
2.6. Neutralization Assays
Neutralization of Env-pseudo-typed reference viruses in TZM-bl cells was performed
at the Duke University HIV neutralization reference laboratory, using established validated
assays and standardized pseudovirus [64,65]. Results are reported as the IC50 , the lowest
concentration yielding >50% inhibition of infectivity. Comparison of data to historical
controls was performed using CATNAP [66]. Statistical comparison of breadth versus
potency curves was performed using a two-tailed, non-parametric Wilcoxon signed rank
test with pairs matched for each isolate.
2.7. Ab-Dependent Phagocytosis
Assays for Ab-dependent phagocytosis (ADP) were performed using the THP-1 monocyte cell line and HIV gp140-coated fluorescent beads using methods similar to those
described [67]. Briefly, 1.8 × 108 neutravidin-coated 1 µm Fluorospheres (Invitrogen)
were treated with 3.5 µg biotin-conjugated rabbit anti-His tag Ab (Pierce), then washed
and reacted with 7 µg His tagged-recombinant gp140SF162 protein (Immune Technology,
New York). After washing, 106 beads per well were incubated at 37 ◦ C for 1 h with triplicate
dilutions of Ab in a V-bottom plate. The Abs were diluted in RPMI 1640 medium containing 10% Ultra-Low (IgG-depleted) FBS (Gibco), penicillin, streptomycin, and L-glutamine.
THP-1 cells (2 × 104 per well) were then added in the same medium and incubated at 37 ◦ C
in 5% CO2 . After 6 h, the cells were washed with Ca+2 /Mg+2 -free DPBS and incubated at
37 ◦ C for 10 min with 50 µL of 0.05% Trypsin/EDTA (Gibco). Cells were washed twice in
DPBS, resuspended in 1% PFA, then examined by flow cytometry. The phagocytic score
was calculated by multiplying the number of bead-positive cells by the median fluorescent
intensity. The phagocytic score of each sample was then divided by the average phagocytic
score obtained with THP-1 in medium alone to obtain the phagocytic score ratio.
3. Results
3.1. Production and Characterization of Immunoadhesins
We have previously described a panel of double variable domain (DVD) Abs that bind
to both gp120 and gp41 using variable domains derived from mAbs to the CD4-binding
site of gp120 (mAb b12) and to the gp41 external loop region (mAb 7B2) [24]. Although
these constructs bound both gp120 and gp41, we did not improve their ability to neutralize
HIV nor to deliver cytotoxic agents to infected cells. However, we did demonstrate that the
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DVD’s worked most efficiently when the gp120-binding domain was at the NH2 -terminus,
joined to the anti-gp41 domain using linkers containing helical, rather than flexible, peptide
domains. Consequently, we designed new constructs to improve neutralization and effector
functions incorporating these design principles, but containing domains of human CD4,
rather than anti-gp120 mAb joined to 7B2 (Figure 1).
We used two forms of CD4: native and CD4(D1.22), which has improved affinity and
neutralizing activity [60]. CD4 was joined to the amino terminus of either H, L, or both
chains of full-length mAb 7B2, a human IgG1/κ anti-gp41 mAb. The H and L chains were
expressed from different plasmids by cotransfection into 293T cells, thus creating CD4/7B2
chimeric Ig-like immunoadhesins with various CD4-Ab conformations and linkers joining
CD4 to 7B2. We tested three different linkers: a flexible linker (GGGGS)4, a helix-creating
sequence [A-(EAAAK)4 -A], and a combination of helical and flexible sequences [(GGGGS)2 (EAAAK)4 -(GGGGS)2 ]. We only obtained the secretion of CD4/7B2 chimeras when CD4
was attached to the heavy chain and when the linker contained helical domains. Constructs
with CD4 attached to either the light chain or to both heavy and light chains failed to
produce antigen-binding protein, as did linkers that solely consisted of flexible domains.
Table 1 describes the nomenclature and construction of the chimeras.
Table 1. Description of CD4-7B2 chimeric immunoadhesins.
Name

H Chain

L Chain

CD4

CD4(D1)-2H2-7B2

CD4(D1)-2H2-7B2

7B2k

CD4(D1.22)

CD4(D1)-H4-7B2

CD4(D1)-H4-7B2

7B2k

CD4(D1.22)

CD4(D2)-2H2-7B2

CD4(D2)-2H2-7B2

7B2k

CD4183

CD4(D2)-H4-7B2

CD4(D2)-H4-7B2

7B2k

CD4183

Linker
(GGGGS)2 A(EAAK)4 A(GGGGS)2
A(EAAK)4 A
(GGGGS)2 A(EAAK)4 A(GGGGS)2
A(EAAK)4 A

Adhesins produced in cell supernatants were purified on protein G agarose and
concentrated. Microcapillary electrophoresis confirmed molecular size and purity of the
H and L chains of the novel constructs (Figure 1C). To compare the functional activity of
the four chimeras described in Table 1 to the parental antibodies, the following samples
were tested side-by-side with them: 1. Irrelevant isotype matched Ig; 2. mAb 7B2 alone;
3. 7B2 + sCD4183 ; 4. CD4-IgG2; and 5. 8ANC195, a human mAb that binds at the
gp120/gp41 interface [36]. Because the activity assays utilize secondary antibodies, we have
kept the concentration of Fc in each preparation the same. In the figures that follow,
immunoadhesins are shown with solid lines and filled symbols, and controls with dotted
lines/open symbols.
3.2. Binding of Immunoadhesins to Antigen
ELISA was used to demonstrate binding of each construct to the gp41 peptide, which is
the target of 7B2, or to trimeric quasi-native gp140. ELISA plates were coated with respective antigens, incubated with serial dilutions of Abs, and probed with an AP-conjugated
anti-human IgG secondary Ab (Figure 2). ELISA binding primarily reflected the binding
activity of 7B2. When tested on the gp41 peptide representing the 7B2 epitope, the mAb
bound far better than the immunoadhesins, and one (CD4(D2)-H4-7B2) failed to bind at all,
indicating that the 7B2 binding site is partially occluded by CD4. As expected, neither CD4IgG2 nor 8ANC195 bound the peptide. Binding to gp140 was similarly limited, with 7B2
mAb producing the best binding, and the adhesins less. Because neither CD4-IgG2 nor
8ANC195 bound to the gp140, there has been some loss of conformational integrity of this
recombinant antigen.
To test recognition of native Env by the chimeras, we used indirect immunofluorescence and flow cytometry to analyze binding to persistently-infected H9/NL4-3 cells,
constitutively expressing Env-transfectants 293/92UG and parental HEK293T cells (Figure 3).
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To test recognition of native Env by the chimeras, we used indirect immunofluorescence and flow cytometry to analyze binding to persistently-infected H9/NL4-3 cells, constitutively expressing Env-transfectants 293/92UG and parental HEK293T cells (Figure 3).
No antibodies or immunoadhesins bound to the uninfected parental cells. The infected
H9/NL4-3 expressed higher levels of antigen on the cell surface than do the transfected
293/92UG. CD4-IgG2 bound best to both the infected and transfected cells, followed
closely by 7B2 in the presence of sCD4183. MAb 7B2 alone bound only weakly. The four
chimeric adhesins bound as well as 7B2 + sCD4183, indicating that there is cooperativity
among the binding sites on the adhesins.
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3.3. Immunoconjugate Cytotoxicity
We have been developing immunoconjugates to deliver cytotoxic agents to HIV-infected cells as a means to eradicate HIV infection. We have compared many mAbs and
have shown that the most potent immunotoxin killing is observed with mAb 7B2 when
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3.3. Immunoconjugate Cytotoxicity
We have been developing immunoconjugates to deliver cytotoxic agents to HIVinfected cells as a means to eradicate HIV infection. We have compared many mAbs and
have shown that the most potent immunotoxin killing is observed with mAb 7B2 when
combined with sCD4 [46–49,68]. Our rationale for constructing these chimeras was to
create a single molecule that could deliver the cytotoxic moiety. To study whether the
CD4/7B2 chimeras function in this regard, we used an indirect immunoconjugate assay
to compare these constructs. H9/NL4-3, 293T, or 293/92UG cells were incubated with
serial dilutions of Ab and then treated with anti-human IgG conjugated to ricin A chain.
Cell viability was measured after 3 days (Figure 4). No cytotoxicity was observed with
the Env(-) HEK/293T cells. Although it appears that the CD4(D1)-2H2-7B2 construct had
modest cytotoxicity against these negative control cells in this experiment, subsequent
experiments at concentrations up to 10X that in Figure 4 showed no toxicity. The H9/NL4-3
cells were less susceptible to immunotoxin killing than 293/92UG, despite having higher
levels of Env on the cell surface (Figure 3), which is an observation we have previously
made [46]. Only 7B2 + sCD4183 killed off H9/NL4-3. HEK293/92UG cells were killed by all
mAbs except the isotype control and 8ANC195. None of the chimeric adhesins functioned
Vaccines 2021, 9, x FOR PEER REVIEW
8 of 15
any better than the parental mAbs. These data indicate that our original rationale for
creating the chimeras may have been incorrect.
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3.4. HIV Neutralization
MAb 7B2 neutralizes HIV weakly, if at all, with results dependent upon the assay
used. CD4-IgG2 contains both the gp120 binding site and an Ab constant region, and is
effective for neutralization. However, CD4-IgG2 is most efficacious against laboratory isolates but had disappointing results in clinical trials [55,56,69]. Thus, there was no reason
to expect that CD4/7B2-Ig chimeras would have great neutralizing activity. However, for
the sake of completeness, we performed preliminary assays measuring neutralization of
live HIV by 7B2, CD4-IgG2, and the immunoadhesins, and observed impressive neutralization results (not shown). We therefore sought to validate these results using a highly
reproducible pseudovirus assay with reference strains of pseudovirions so that the neutralizing activity of our immunoadhesins could be compared to that of other broadly-reactive, highly-potent, neutralizing mAbs [64,65]. Figure 5A shows a potency vs breadth
plot of the neutralizing activity of the chimeric adhesins and controls against 44 different
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3.4. HIV Neutralization
MAb 7B2 neutralizes HIV weakly, if at all, with results dependent upon the assay
used. CD4-IgG2 contains both the gp120 binding site and an Ab constant region, and is
effective for neutralization. However, CD4-IgG2 is most efficacious against laboratory
isolates but had disappointing results in clinical trials [55,56,69]. Thus, there was no reason
to expect that CD4/7B2-Ig chimeras would have great neutralizing activity. However,
for the sake of completeness, we performed preliminary assays measuring neutralization
of live HIV by 7B2, CD4-IgG2, and the immunoadhesins, and observed impressive neutralization results (not shown). We therefore sought to validate these results using a highly
reproducible pseudovirus assay with reference strains of pseudovirions so that the neutralizing activity of our immunoadhesins could be compared to that of other broadly-reactive,
highly-potent, neutralizing mAbs [64,65]. Figure 5A shows a potency vs breadth plot of
the neutralizing activity of the chimeric adhesins and controls against 44 different tier 1
and 2 pseudoviruses. A spreadsheet of the raw IC50 data is included as Supplementary
Table S1. The “positive control” in this assay is a mixture of two different highly potent
neutralizing mAbs CH01 and CH31. Mab 7B2 has no neutralization activity in this assay.
CD4-IgG2 shows modest neutralization with 50% of isolates neutralized at ~3 µg/mL.
Mixing 7B2 and CD4183 was less effective with 50% of isolates neutralized at 10 µg/mL.
However when CD4 and 7B2 were combined into a single molecule, synergistic effects
were observed, with all four chimeric immunoadhesins showing significantly greater neutralization (by Wilcoxon matched pairs signed rank test, Table S1) than either 7B2+CD4183
or CD4-IgG2. Those adhesins based on the CD4(D1.22) construct had 10–30-fold improved
neutralization compared to those based on the native CD4 sequence (p < 0.001), consistent
with previously published results comparing CD4(D1.22) to wild-type CD4 [60]. The role
of the linker between CD4 and 7B2 heavy chain were minor. Comparing the CD4(D1)
constructs, the H4 linker appeared better than 2H2, but with CD4(D2) chimeras, the reverse
was observed. In Figure 5B, we used the CATNAP database [66] to compare breadth
and potency of neutralization by the immunoadhesins to historical data from a panel of
well-described, highly-potent, broadly-neutralizing anti-HIV mAbs. All were compared
on the same pseudovirus isolates. The graph in the upper left shows our experimental
data compared to the historical data for mAb 8ANC195, yielding essentially overlapping
curves. The data demonstrate that while some of the mAbs were more potent (e.g., 35O22,
PGDM1400, and PGT145), they demonstrated less breadth. Only VRC07-523, a CD4 binding
site-specific mAb that is undergoing clinical trials, had equivalent breadth and somewhat
greater potency. The neutralization patterns observed with the CD4/7B2 chimeras most
closely resembled those of the two mAbs directed against the membrane proximal external
region of gp41: 10E8 and 4E10.
3.5. Ab-Dependent Phagocytosis
Fc-mediated effector functions are critical for the ability of even neutralizing Abs
to function most effectively in vivo [16,37–45]. Other Fc-mediated antiviral effects of Ab
include phagocytosis of virions [67], lysis of HIV-infected cells by ADCC [44,45], or a combination of these activities [70]. We tested our panel of CD4/7B2 chimeras and controls for
their ability to opsonize fluorescent microspheres coated with oligomeric gp140 for ingestion by THP-1 cells (Figure 6). Among the parental mAbs, 7B2 was consistently better than
CD4-IgG2 at mediating ADP. We cannot say with certainty if this is a function of epitope
specificity (gp41 better than gp120), or the isotype of the Ab (IgG1 vs. IgG2). When CD4183
was added to 7B2, greater phagocytosis is observed. The four immunoadhesins all mediated
ADP, approximately as well as 7B2 alone, but not as well 7B2 + CD4183 .

curves. The data demonstrate that while some of the mAbs were more potent (eg 35O22,
PGDM1400, and PGT145), they demonstrated less breadth. Only VRC07-523, a CD4 binding site-specific mAb that is undergoing clinical trials, had equivalent breadth and somewhat greater potency. The neutralization patterns observed with the CD4/7B2 chimeras
most closely resembled those of the two mAbs directed against the membrane proximal
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external region of gp41: 10E8 and 4E10.
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Figure 5. Neutralization by mAbs and Ig-Adhesins. Neutralization was studied using the TZM-bl assay with 44 different
tier 1 and 2 pseudotyped HIV isolates (A). The panel of mAbs and Ig-adhesins, along with a mixture of CH01+CH31
neutralizing mAbs was tested for potency and breadth of neutralization. Vertical axis is percentage of isolates neutralized,
the horizontal is IC50 (µg/mL) (B). Comparison of experimental results with historical data in CATNAP. The upper left
panel compares mAb 8ANC195 experimental vs historical data. The remainder compare two Ig-Adhesins to other potent,
broadly-neutralizing mAbs. Axes are the same.
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bination of these activities [70]. We tested our panel of CD4/7B2 chimeras and controls for
their ability to opsonize fluorescent microspheres coated with oligomeric gp140 for ingestion by THP-1 cells (Figure 6). Among the parental mAbs, 7B2 was consistently better than
CD4-IgG2 at mediating ADP. We cannot say with certainty if this is a function of epitope
specificity (gp41 better than gp120), or the isotype of the Ab (IgG1 vs. IgG2). When CD4
10 of183
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was added to 7B2, greater phagocytosis is observed. The four immunoadhesins all mediated ADP, approximately as well as 7B2 alone, but not as well 7B2 + CD4183.
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L chain, or both chains of the anti-gp41 mAb 7B2. Constructs in which CD4 was attached
to the L chain were not secreted in sufficient quantity to analyze. We then compared
these four immunoadhesins (two different CD4 constructs and two different linkers for
each) to the parental proteins (7B2 and sCD4) individually and in combination, and to the
well-established broadly neutralizing mAb 8ANC195, which binds determinants at the
interface of gp120 and gp41. In general, the function of the chimeric immunoadhesins was
intermediate between that of the parental components, with the exception of neutralization
(Figure 5). We were surprised to find that our CD4/7B2 constructs had potent and very
broad neutralizing activity. As for their ability to deliver cytotoxic immunoconjugates,
the function for which they were designed, the chimeric constructs were not equal to a
mixture of the two parentals.
MAb 7B2 neutralizes only weakly, if at all (Figure 5A), although recent studies suggest
that mAbs to this region may have neutralizing potential when engaged by FcγRI [71].
It binds well to a highly conserved epitope. Beyond the additive neutralization of 7B2 and
sCD4, other factors may play a role in the enhanced neutralization efficacy of the CD4/7B2
chimeras over the original parental components. Cross-linking of gp120 to gp41 by the
bispecific immunoadhesin may be one such mechanism. The dissociation of gp120 from
gp41 is a critical step in Env-mediated virus/cell fusion and infection. Natural mAbs and
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genetic constructs that bind to both gp120 and gp41 have been described, which neutralize
HIV quite well [25,34,35], providing support for this hypothesis. However, other mAbs and
constructs with demonstrated binding to both gp120 and gp41 neutralize poorly [24,33],
suggesting other mechanisms are also involved.
We have found that combining two different gp160-binding domains on one molecule
has differential effects on different functions of the chimeric adhesin: neutralization is
markedly enhanced (Figure 5), whereas the ability to deliver a cytotoxic immunoconjugate
is diminished (Figure 4). The discrepancy between neutralization and cytotoxicity is
not unexpected, since cytotoxicity requires binding, internalization, intracellular routing,
and processing of the cytotoxic conjugate [48,72,73]; whereas neutralization primarily
occurs before the virus can enter the cell. In previous work, we showed that there is little
correlation between the cytotoxic activity of different anti-gp160 mAbs and their ability
to bind cell-surface Env or neutralize a virus secreted by those cells [46]. These results
emphasize the notion that for anti-HIV Env Abs, and probably other antiviral mAbs,
analysis of binding function and neutralization may not fully define their functional
activity and therapeutic utility. This is consistent with findings that emphasize the role of
Fc-mediated effector function in protective efficacy [16,37–45]. To enhance the antiviral
utility of the CD4/7B2 chimeric adhesins described here, we engineered the Fc-associated
glycans and studied the effects of these altered glycans on Fc-mediated effector functions.
5. Conclusions
We describe the production of engineered immunoadhesins that bind to both gp120
and gp41 of the HIV-envelope. The adhesin contains CD4 to bind gp120, and the anti-gp41
mAb 7B2. We tested these adhesins for binding, effector function, virus neutralization,
and the ability to deliver cytotoxic immunoconjugates. In most assays, these adhesins
functioned as well as either of the parental molecules. However, the adhesins showed
broad and potent HIV-neutralizing activity exceeding that of either parent, even when
7B2 and CD4 were mixed together. These adhesins may be used therapeutically to treat
active infection or to eliminate reservoirs of HIV-infected cells that persist despite antiviral
therapy. This study also informs us about how Abs neutralize HIV, suggesting that by
binding to both portions of the envelope, these Abs neutralize viruses by limiting the
structural changes in the envelope that are necessary to cause infection.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/vaccines9070774/s1, Table S1: Neutralization: raw data and statistical analyses.
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